← Back to feedRead original →
VERIFIEDMint Markets·neutral
After a dull Q4, Glenmark Pharma needs a booster shot to grow
AI Summary
- ·Glenmark Pharma is focusing on core operational execution for FY27 growth.
- ·The company is looking past one-off licensing gains.
- ·Investors are shifting their focus to operational execution.